ストックスクリーナーアプリを入手
266.97
0.35%
-0.95
アフターアワーズ：
266.97
Ascendis Pharma A S (ASND) 最新ニュース
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia - marketscreener.com
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TipRanks
Ascendis Pharma A/SAnnounces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia - TradingView
Ascendis drug data show leg alignment kept improving through 2 years - Stock Titan
Children with Achondroplasia Treated with TransCon CNP - GlobeNewswire
Big Pharma Has a Case of Merger Mania - The Motley Fool
Ascendis Pharma A/S(NasdaqGS:ASND) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital - TipRanks
Ascendis Pharma (ASND) adds 177,267 shares via warrant exercises - Stock Titan
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 2500 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Growth Benchmark - marketscreener.com
Sit Mid Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $288 - 富途牛牛
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Index - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Value Benchmark - marketscreener.com
Ascendis Pharma (ASND) moves 9.9% higher: Will this strength last? - MSN
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000 Value Benchmark - marketscreener.com
Ascendis Pharma added to Russell 1000 and other indexes By Investing.com - Investing.com Australia
Ascendis Pharma joins multiple Russell U.S. indexes, boosting its market visibility. - Pluang
Ascendis Pharma added to Russell 1000 and other indexes - Investing.com UK
Ascendis Pharma (ASND) Joins Russell Indexes in 2026 Reconstitution - GuruFocus
Ascendis Pharma (ASND) Joins Multiple Russell Indexes - GuruFocus
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap - marketscreener.com
Ascendis Joins Multiple Russell U.S. Indexes, Including the - GlobeNewswire
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout | AI
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance
Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026. - Pluang
Ascendis to show 104-week achondroplasia data in Montreal - Stock Titan
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewswire
Ascendis Pharma jumps as investors weigh cash boost, pipeline momentum, and possible index-related buying - Quiver Quantitative
Ascendis Pharma (ASND) Could Be 30% Undervalued Following Mixed Share Price Moves - simplywall.st
(ASND) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Final Trades: Ascendis Pharma, Monolithic Power, The IYC And The GPIQ Corinthians X São Paulo (waHz3aMVr9) - Mshale
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating - 富途牛牛
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A/S (ASND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $326 - 富途牛牛
Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ascendis Pharma A/S (ASND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale - Stock Titan
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $262 - 富途牛牛
Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says - marketscreener.com
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):